Get started

Press Releases

Delayed 3m

Fastest customizable press release feed in the world.

Signed out · 3-min delay · Sign up for real-time

Updates arrive automatically.

  • RedCloud to Participate in the 15th Annual ROTH Technology Conference
    PR·

    RedCloud to Participate in the 15th Annual ROTH Technology Conference

    RedCloud Holdings plc (NASDAQ:RCT) ("RedCloud" or the "Company"), which is building the AI prediction infrastructure for global FMCG trade, today announced that Justin Floyd, Chief Executive Officer, will attend and host one-on-one meetings at the 15th Annual ROTH Technology Conference November 17-18, 2026 in New York City. For conference details or to schedule a one-on-one meeting, please contact your ROTH representative. To learn more and submit a registration request, visit http://www.roth.com/tech2026. Mr. Floyd will also be in New York City before and after the conference, and meetings can be arranged by contacting RedCloud’s investor relatio

    $RCT
  • Tyler Technologies to Participate in November and December Investor Conferences
    PR·

    Tyler Technologies to Participate in November and December Investor Conferences

    Tyler Technologies, Inc. (NYSE:TYL) will participate in five investor conferences in November and December 2026. Conference Date Time and Place Participant(s) Northcoast Research Fall Management Forum Nov. 9 1x1 meetings by appointment Virtual Hala Elsherbini, senior director of investor relations Aron Carr, director of corporate financial planning and analysis Tom Prohonic, vice president and corporate treasurer 7th Annual Needham Virtual Tech Week Nov. 20 1x1 meetings by appointment Virtual Brian Miller, executive vice president and chief financial officer Hala Elsh

    $TYL
  • TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
    PR·

    TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition

    Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing cells in cancer and autoimmune disease including MDSCs, T regs, and M2 macrophages

    $HURA
  • Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
    PR·

    Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

    Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDSThree poster presentations will highlight data for TAVALISSE® (fostamatinib disodium hexahydrate) in patients with chronic

    $RIGL
  • Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
    PR·

    Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

    – iMMagine-1 Data Provide 18 Months Minimum Follow-Up on Anito-cel’s Durability and Safety in Relapsed or Refractory Multiple Myeloma – – Five-Year ZUMA-12 Follow-Up Data to Provide Long-Term Evidence for Yescarta® in First-Line High-Risk Large B-cell Lymphoma – Gilead Sciences, Inc. (NASDAQ:GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026). These latest clinical milestones demonstrate transformative progress across Gilead and Kite’s pipeline and portfolio, from new data for the investigational anitocabtagene autoleuc

    $GILD
  • Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
    PR·

    Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026

    Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 12-15, 2026, in New Orleans, Louisiana. Abstract 4498 – Oral Presentation Title: What to expect during the first 3 months post obecabtagene autoleucel (obe-cel) infusion in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL): A deepening of measurable residual disease (MRD) respon

    $AUTL
  • Terreno Realty Corporation Announces Lease in Avenel, NJ
    PR·

    Terreno Realty Corporation Announces Lease in Avenel, NJ

    Terreno Realty Corporation (NYSE:TRNO), an acquirer, owner and operator of industrial real estate in six major coastal U.S. markets, announced today that it has executed a lease for 82,000 square feet in Avenel, New Jersey with a third-party logistics provider. The lease will commence February 1, 2027 and will expire April 2032. Terreno Realty Corporation acquires, owns and operates industrial real estate in six major coastal U.S. markets: New York City/Northern New Jersey; Los Angeles; Miami; San Francisco Bay Area; Seattle; and Washington, D.C. Additional information about Terreno Realty Corporation is available on the company’s web site at www.terreno.com. Forward-Looking Statement

    $TRNO
  • Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
    PR·

    Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting

    Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that two of its T cell engager programs, CLN-049, a FLT3xCD3 T cell engager, and velinotamig (CLN-803), a BCMAxCD3 T cell engager, will be featured across four poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15 in New Orleans, Louisiana. Cullinan will present updated data from the CLN-049 Phase 1 dose escalation study in patients with relapsed or r

    $CGEM
  • U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma
    PR·

    U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma

    If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphoma Application supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximab Full MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (s

    $ONC
  • Agilent Completes Acquisition of Proscia
    PR·

    Agilent Completes Acquisition of Proscia

    Expands Agilent’s pathology portfolio and establishes a platform for scientific intelligence in tissue-based precision medicine Strengthens Agilent’s ability to support customers across clinical diagnostics, biopharma and life-sciences research Agilent Technologies Inc. (NYSE:A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of th

    $A
  • Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
    PR·

    Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease

    The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseasesPhase 1b/2 trial evaluates targeted immune conditioning with Iomab-ACT before standard commercial CD19-directed CAR T-cell therapyMemorial Sloan Kettering Cancer Center study demonstrates promise of Iomab-ACT as targeted conditioning agent before CAR T-cell therapy, with a focus on CAR T-cell expansion, immune cell depletion and treatment-related toxicitiesClinical experience in severe sickle cell disease evaluates Iomab-ACT-based conditioning to support donor engraftment without conventional chemotherapy

    $ATNM
  • Harsco Rail Executes Agreement to Exit Deutsche Bahn Engineered-to-Order Contract and Receives Initial Payment from Sale of Project Assets to GBM
    PR·

    Harsco Rail Executes Agreement to Exit Deutsche Bahn Engineered-to-Order Contract and Receives Initial Payment from Sale of Project Assets to GBM

    Deutsche Bahn (DB) agreement fully releases Harsco Rail from its obligations under the ETO contract, including elimination of its $13 million in performance bonds Harsco Rail received approximately $8 million in September from its former subcontractor General Atomics, Gleisbaumechanik Brandenburg GmbH (GBM), pursuant to an asset sales agreement related to the DB contract; Enviri expects to receive remaining payments of approximately $34 million in the coming quarters, including $15-18 million in 2026Enviri to record a net gain of approximately $19 million as a result of the GBM payment and with the execution of the

    $NVRI
  • Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
    PR·

    Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML

    Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemiaLong-term follow-up evaluates bone marrow recovery and potential delayed kidney and liver toxicities following Actimab-A plus intensive salvage chemotherapyFindings support development of Actimab-A as a potential mutation-agnostic AML backbone, building on prior clinical activity following venetoclax failure and in TP53-mutated disease

    $ATNM
  • SoundHound AI and Ultraviolette Announce Major Expansion of Agentic Voice AI Across Global Electric Vehicle Lineup
    PR·

    SoundHound AI and Ultraviolette Announce Major Expansion of Agentic Voice AI Across Global Electric Vehicle Lineup

    SOUN), a global leader in voice and agentic AI, and Ultraviolette Automotive, an innovator in future-ready electric mobility platforms and battery technology, today announced a major commercial expansion, with SoundHound set to power Ultraviolette’s voice AI co-pilot." data-filename="Press Release_SH x Ultraviolette Logo Lockup_Thumbnail_Plum.png">

    $SOUN
  • Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
    PR·

    Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

    First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study Preclinical data show HMB-003 reduced severe menstrual bleeding in a cynomolgus monkey model of menstrual bleeding

    $COAG
  • Feedonomics Now Available in Amazon’s Shop Direct Merchant Workspace, Making it Easier for Brands to Get Their Products in Front of Amazon Customers
    PR·

    Feedonomics Now Available in Amazon’s Shop Direct Merchant Workspace, Making it Easier for Brands to Get Their Products in Front of Amazon Customers

    Commerce.com (NASDAQ:CMRC), the parent company of product intelligence platform Feedonomics, today announced that Feedonomics is available as a solution provider in Amazon's new Shop Direct Merchant Workspace, a free self-service portal that makes it easy for eligible merchants to register for Shop Direct, connect their stores to Amazon, and manage their participation in Amazon's agentic shopping program. Through the Merchant Workspace, eligible U.S. brands and retailers can select Feedonomics as their solution provider to connect their existing product catalogs to Shop Direct — using feeds they've already built for other shopping destinati

    $CMRC
  • Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference
    PR·

    Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference

    Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience, is scheduled to present at Stifel’s 2026 Healthcare Conference happening November 10 – 12, 2026 in New York, New York. Presentation Details Presenter: Sabrina Martucci Johnson, Founder, President and Chief Executive OfficerDate: Wednesday, November 11, 2026Time: 11:20 a.m.–11:50 a.m. ETLocation: Lotte New York Palace Hotel, 5th Floor – HubbardLive Webcas

    $DARE
  • Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
    PR·

    Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

    Two oral presentations featuring additional data from RALLY-MF Phase 2 trial of selcodebart (DISC-0974) in anemia of myelofibrosis (MF) and RESTORE-PV Phase 2 trial of DISC-3405 in polycythemia vera (PV)Oral presentation highlighting inhibition of glycine transporter 1 reduced chronic inflammation and improved red blood cell health in a mouse model of erythropoietic protoporphyria (EPP)Poster presentations across all programs, including initial data from Phase 1b trial of DISC-3405 in sickle cell disease (SCD), baseline characteristics from Phase 3 APOLLO trial of bitopertin in EPP, and new translational data in preclinical models supporting use in existing and additional indicationsManageme

    $IRON
  • Penguin Solutions Announces Agreement to Sell Cree LED to Transom Capital Group
    PR·

    Penguin Solutions Announces Agreement to Sell Cree LED to Transom Capital Group

    Transaction marks another milestone in Penguin’s transformation into a pure-play data center AI infrastructure solutions company Penguin Solutions, Inc. ("Penguin Solutions," "Penguin," or the "Company") (NASDAQ:PENG), the AI Factory Platform Company, today announced that it has entered into a definitive agreement to sell its Cree LED business ("Cree LED") to Transom Capital Group ("Transom"), a leading operations-focused middle-market private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104524800/en/ The planned divestiture reflects Penguin Solutions’ commitment to creating long-term shareholder value. It wi

    $PENG
  • Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
    PR·

    Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission

    Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors. Ronde-cel, a next-generation CD19/CD20 CAR T-cell product candidate, is advancing toward pivotal data in mid-2027, with the potential to deliver meaningful and durable clinical benefit for patients with relapsed/refractory large B-cell lymphomaProceeds expected to extend cash runway into 2028, beyond anticipated BLA submission for ronde-cel in the second half of 2027, as well as updated clinical data from our GCC-targeted LYL273 program for patients with metastatic colorectal cancer SOUTH SAN FRANCISCO, Calif., N

    $LYEL